- Home
- AU vs ROIV Comparison
AU vs ROIV Comparison
Compare AU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- ROIV
- Stock Information
- Founded
- AU 1944
- ROIV 2014
- Country
- AU United States
- ROIV United Kingdom
- Employees
- AU N/A
- ROIV N/A
- Industry
- AU Precious Metals
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AU Basic Materials
- ROIV Health Care
- Exchange
- AU Nasdaq
- ROIV Nasdaq
- Market Cap
- AU 10.3B
- ROIV 8.4B
- IPO Year
- AU 1972
- ROIV N/A
- Fundamental
- Price
- AU $26.75
- ROIV $11.07
- Analyst Decision
- AU Hold
- ROIV Strong Buy
- Analyst Count
- AU 5
- ROIV 8
- Target Price
- AU $31.75
- ROIV $17.93
- AVG Volume (30 Days)
- AU 2.5M
- ROIV 5.3M
- Earning Date
- AU 11-07-2024
- ROIV 02-11-2025
- Dividend Yield
- AU 0.84%
- ROIV N/A
- EPS Growth
- AU N/A
- ROIV N/A
- EPS
- AU 1.34
- ROIV 5.89
- Revenue
- AU $5,299,000,000.00
- ROIV $129,128,999.00
- Revenue This Year
- AU $31.38
- ROIV $15.98
- Revenue Next Year
- AU $28.36
- ROIV N/A
- P/E Ratio
- AU $18.96
- ROIV $1.86
- Revenue Growth
- AU 17.78
- ROIV 145.68
- 52 Week Low
- AU $15.80
- ROIV $9.69
- 52 Week High
- AU $32.57
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AU 62.39
- ROIV 41.31
- Support Level
- AU $25.26
- ROIV $10.42
- Resistance Level
- AU $26.24
- ROIV $11.25
- Average True Range (ATR)
- AU 0.54
- ROIV 0.34
- MACD
- AU 0.42
- ROIV -0.09
- Stochastic Oscillator
- AU 95.13
- ROIV 36.24
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.